Vt. Blok et al., A possible role of CD46 for the protection in vivo of human renal tumor cells from complement-mediated damage, LAB INV, 80(3), 2000, pp. 335-344
It is still unclear which membrane-bound regulatory proteins (mCRP) are imp
ortant in vivo to protect tumor cells from complement-mediated damage. To a
ddress this question, the expression levels of CD46, CD55, and CD59 were me
asured semi-quantitatively in situ on renal cell carcinomas and compared wi
th the expression level and cellular distribution of these mCRP in proximal
tubuli within each patient (n = 31). It was also determined whether the ex
pression of mCRP on tumor cells is associated with deposition of C3d and C5
b-9. CD46 expression was decreased on tumor cells; in contrast, CD55 was ex
pressed on tumor cells (12 out of 31 samples), while it was not detected on
proximal tubular epithelial cells (PTEC). Also, expression of CD59 on tumo
r cells was increased as compared with its expression on PTEC. Furthermore,
the localization on the cell surface of mCRP as observed on PTEC was alter
ed on tumor cells. Because expression of mCRP may limit a complement-mediat
ed anti-tumor response, we determined whether complement deposition was ass
ociated with the expression level of CD46, CD55, and CD59. The presence of
C3d on tumor cells was associated with a low expression level of CD46 (p <
0.02). The expression level of CD46 was also associated with a low tumor st
age lo (p < 0.04). The results suggest that in vivo CD46 plays a role in th
e protection of human renal tumor cells from complement-mediated injury.